ARTICLE | Clinical News
BM32: Phase IIb data
February 9, 2015 8:00 AM UTC
Data from 141 evaluable patients with grass pollen allergy in a double-blind, European Phase IIb trial showed that subcutaneous BM32 improved the mean daily combined symptom and medication score, the ...